Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in pulmonary arterial hypertension
2021-000670-28Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing LTP001 with Placebo (2 arms). Primary endpoint: Change from baseline pulmonary vascular resistance at week 25. Started Nov 2021; status: terminated.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-000670-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000670-28.